CANVAS & RFC1 Spectrum Disorder
Cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS) is an autosomal recessive neurodegenerative disorder caused by biallelic intronic AAGGG repeat expansions in the RFC1 (Replication Factor C subunit 1) gene. First described clinically as a distinct syndrome in 2011 (Szmulewicz et al.), its genetic basis was identified in 2019 by Cortese et al. and Rafehi et al. RFC1-related disease is now recognized as one of the most common inherited ataxias in adults, with a carrier frequency of the pathogenic AAGGG expansion estimated at 0.7–4% across European populations.
Bottom Line
- Genetics: Biallelic AAGGG pentanucleotide repeat expansion in intron 2 of RFC1; autosomal recessive; normal allele has AAAAG repeats; carrier frequency 0.7–4% in Europeans
- Clinical triad: Cerebellar ataxia + sensory neuropathy (ganglionopathy) + bilateral vestibular areflexia; not all three required at presentation
- Distinctive features: Chronic cough (up to 60%), autonomic dysfunction (orthostatic hypotension, dry mouth/eyes), dysphagia; typically presents after age 50
- MRI: Cerebellar vermis and hemispheric atrophy; pseudo–eye-of-the-tiger sign in globus pallidus has been reported
- Expanding phenotype: RFC1 expansions also cause pure sensory neuropathy, isolated vestibular dysfunction, and late-onset ataxia without the full CANVAS triad
- No disease-modifying treatment: Management is supportive — vestibular rehabilitation, balance training, assistive devices, cough management
Genetics
RFC1 Gene & Repeat Expansion
The RFC1 gene (chromosome 4p14) encodes a subunit of the replication factor C complex involved in DNA replication and repair. The pathogenic mechanism involves a biallelic intronic pentanucleotide repeat expansion:
| Repeat Motif | Status | Notes |
|---|---|---|
| AAAAG | Normal (reference allele) | ~11 repeats in reference genome; up to ~200 repeats are non-pathogenic |
| AAGGG | Pathogenic | Expanded to ~400–2000+ repeats; biallelic AAGGG = CANVAS/RFC1 spectrum |
| ACAGG | Pathogenic (Maori variant) | Identified in Maori and Pacific Island populations; causes same phenotype |
| AAAGG | Likely benign (non-pathogenic expansion) | Common in population; not associated with disease even when biallelic and expanded |
| AAGAG | Pathogenic | Rare alternate pathogenic configuration |
Diagnostic Testing Considerations
Standard next-generation sequencing and whole-exome sequencing cannot detect RFC1 repeat expansions. Diagnosis requires flanking PCR (screening for expanded alleles), followed by repeat-primed PCR or Southern blot to confirm the expansion motif. Long-read sequencing (Oxford Nanopore, PacBio) can directly characterize the repeat motif and size. Importantly, the non-pathogenic AAAGG expansion is common and must be distinguished from pathogenic AAGGG — motif-specific repeat-primed PCR is essential.
Epidemiology
- Carrier frequency: 0.7–4% for pathogenic AAGGG expansion across European populations
- Estimated prevalence: Likely the most common recessive ataxia in adults alongside Friedreich ataxia; accounts for ~12–15% of undiagnosed late-onset cerebellar ataxias in some series
- Geographic distribution: Most studied in European and Australian populations; the ACAGG variant is prevalent in Māori/Pacific Island populations
- Age of onset: Typically >50 years (range 35–75); men and women equally affected
Clinical Features
Classic CANVAS Triad
| Component | Clinical Manifestation | Assessment |
|---|---|---|
| Cerebellar Ataxia | Progressive gait and limb ataxia; dysarthria; ocular motor dysfunction (downbeat nystagmus, broken smooth pursuit, saccadic intrusions) | SARA scale; tandem gait; finger-to-nose/heel-to-shin testing |
| Sensory Neuropathy (ganglionopathy) | Loss of proprioception and vibration sense; sensory ataxia that compounds the cerebellar component; areflexia; positive Romberg sign; painless sensory loss in large-fiber distribution | Nerve conduction studies: absent or reduced sensory nerve action potentials (SNAPs) with normal motor conduction; sural nerve biopsy shows chronic axonal loss |
| Bilateral Vestibular Areflexia | Oscillopsia during head movement; impaired vestibulo-ocular reflex (VOR); postural instability especially in dark or on uneven surfaces; worsening imbalance with eyes closed | Abnormal head impulse test (bilateral); absent caloric responses; reduced or absent VOR on video head impulse testing (vHIT) |
Non-Triad Features
CANVAS is increasingly recognized as a multisystem disorder with features beyond the classic triad:
| Feature | Frequency | Details |
|---|---|---|
| Chronic cough | Up to 60% | Dry, nonproductive; may precede neurologic symptoms by years to decades; thought to result from vagal neuropathy; often misdiagnosed as asthma, GERD, or idiopathic cough |
| Autonomic dysfunction | 30–50% | Orthostatic hypotension, urinary dysfunction (urgency, frequency, retention), dry mouth (xerostomia), dry eyes (keratoconjunctivitis sicca), constipation, erectile dysfunction |
| Dysphagia | 20–40% | Oropharyngeal dysphagia; aspiration risk in advanced disease |
| Neuropathic pain | ~15% | Can occur despite predominantly large-fiber neuropathy; may respond to gabapentin/pregabalin |
| Dizziness / vertigo | Common | Often presenting symptom; may be episodic before becoming chronic; attributed to vestibular dysfunction |
Chronic Cough as a Diagnostic Clue
A chronic, unexplained dry cough in a patient with late-onset ataxia and/or sensory neuropathy is highly suggestive of CANVAS/RFC1 disease. The cough results from vagal sensory neuropathy affecting the airway cough reflex. It may be the earliest symptom, preceding cerebellar signs by up to 20 years, and is often unresponsive to standard cough therapies. Recognition of this association can prompt earlier genetic testing and diagnosis.
Incomplete Phenotypes
Not all patients with biallelic RFC1 expansions present with the full CANVAS triad. Recognized incomplete phenotypes include:
- Isolated sensory neuropathy — pure large-fiber sensory ganglionopathy without ataxia or vestibular loss
- Isolated cerebellar ataxia — late-onset cerebellar syndrome without neuropathy or vestibular involvement
- Sensory neuropathy + vestibular areflexia without overt cerebellar signs
- Chronic cough + neuropathy without other features
These incomplete presentations may represent earlier disease stages, as additional features can develop over time.
Investigations
| Investigation | Expected Findings |
|---|---|
| Brain MRI | Cerebellar atrophy (vermis and hemispheres); brainstem atrophy in advanced cases; pseudo–eye-of-the-tiger sign in globus pallidus reported in some patients |
| Nerve conduction studies | Non-length-dependent pattern: absent or reduced SNAPs diffusely; normal motor conduction; consistent with sensory ganglionopathy rather than length-dependent polyneuropathy |
| Vestibular testing | Bilaterally abnormal video head impulse test (vHIT); absent caloric responses; reduced vestibular-evoked myogenic potentials (VEMPs) |
| Genetic testing | Biallelic pathogenic expansion in RFC1 (AAGGG or ACAGG motif) — requires flanking PCR + repeat-primed PCR (standard NGS insufficient) |
| Otolaryngology evaluation | Rule out other causes of chronic cough; audiometry (hearing typically normal unless concurrent condition) |
| Autonomic testing | May show orthostatic hypotension, reduced heart rate variability, sudomotor dysfunction |
Differential Diagnosis
| Condition | Distinguishing Features |
|---|---|
| Friedreich ataxia | Younger onset (<25); cardiomyopathy; scoliosis; GAA expansion in FXN; absent reflexes but with pyramidal signs (upgoing toes) |
| MSA-C | Parkinsonism; severe autonomic failure; rapid progression; hot cross bun sign; no sensory neuropathy typically |
| SCA27b (FGF14) | Autosomal dominant; downbeat nystagmus prominent; no neuropathy or vestibular loss |
| Anti-GAD cerebellar ataxia | Autoimmune; high anti-GAD65 titers; may respond to immunotherapy; no neuropathy typically |
| Sjögren syndrome neuropathy | Sensory ganglionopathy overlap; but anti-SSA/SSB positive; dry mouth/eyes (also in CANVAS); rare cerebellar involvement |
| POLG-related ataxia | Mitochondrial; progressive external ophthalmoplegia; myopathy; liver involvement; elevated CK/lactate |
| Paraneoplastic cerebellar degeneration | Subacute onset (weeks); associated malignancy; onconeural antibodies (Yo, Hu); usually no neuropathy in isolation |
| Idiopathic late-onset cerebellar ataxia (ILOCA) | Diagnosis of exclusion; no neuropathy or vestibular loss; genetic testing negative (CANVAS may be misdiagnosed as ILOCA) |
Management
No disease-modifying therapy exists for CANVAS/RFC1 spectrum disorder. Management is multidisciplinary and supportive:
| Domain | Approach |
|---|---|
| Vestibular rehabilitation | Specialized physical therapy focusing on gaze stabilization exercises, balance training, and habituation; critical for managing bilateral vestibular loss |
| Falls prevention | Home safety assessment; assistive devices (cane, walker); fall detection wearables; night lights (vestibular patients are worse in dark) |
| Chronic cough | Speech pathology for cough suppression techniques; gabapentin or pregabalin may help neurogenic cough; avoid unnecessary asthma/GERD medications |
| Autonomic dysfunction | Orthostatic hypotension: compression stockings, increased fluid/salt, fludrocortisone, midodrine; bladder: anticholinergics or intermittent catheterization |
| Dysphagia | Swallowing evaluation; dietary modifications; PEG tube consideration if recurrent aspiration |
| Neuropathic pain | Gabapentin, pregabalin, duloxetine |
| Psychological support | Screening for depression and anxiety; genetic counseling for family members |
Prognosis
- CANVAS is slowly progressive over decades; the rate of progression is generally slower than MSA or many SCAs
- Many patients maintain independent ambulation for 10–15+ years after symptom onset; wheelchair dependency may eventually occur
- The combination of cerebellar, proprioceptive, and vestibular deficits creates a “triple hit” to balance that is particularly disabling
- Aspiration pneumonia from dysphagia is a significant risk in advanced disease
- Life expectancy data are limited but life span may not be markedly shortened in many patients
- Genetic counseling: autosomal recessive — siblings have a 25% risk; carrier testing available for family members
References
- Zesiewicz TA. Ataxia. Continuum (Minneap Minn). 2025;31(4, Movement Disorders):1093–1119.
- Cortese A, Simone R, Sullivan R, et al. Biallelic expansion of an intronic repeat in RFC1 is a common cause of late-onset ataxia. Nat Genet. 2019;51(4):649–658.
- Rafehi H, Szmulewicz DJ, Bennett MF, et al. Bioinformatics-based identification of expanded repeats: a non-reference intronic pentanucleotide expansion in RFC1 causes CANVAS. Am J Hum Genet. 2019;105(1):151–165.
- Szmulewicz DJ, Waterston JA, Halmagyi GM, et al. Sensory neuropathy as part of the cerebellar ataxia neuropathy vestibular areflexia syndrome. Neurology. 2011;76(22):1903–1910.
- Cortese A, Reilly MM, Houlden H. RFC1 CANVAS/Spectrum Disorder. In: Adam MP, et al., eds. GeneReviews. University of Washington, Seattle; 2020.
- Abreu VS, Silva JS, Igreja L, et al. Pseudo–eye-of-the-tiger sign in CANVAS. Am J Med Genet A. 2024;194(1):103–106.
- Traschütz A, Cortese A, Reich S, et al. Natural history, phenotypic spectrum, and discriminative features of multisystemic RFC1 disease. Neurology. 2021;96(9):e1369–e1382.